X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Pelosi’s radical plan would leave Alzheimer’s patients behind

By Tom Wilbur  |    October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and leave...   Read More

Event tomorrow: Maintaining America’s leadership in access and innovation

By Andrew Powaleny  |    October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high levels...   Read More

What they are saying: Broad opposition to Pelosi’s radical drug pricing plan

By Tom Wilbur  |    October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An increasing...   Read More

On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions

By Megan Van Etten  |    October 4, 2019
Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and...   Read More

By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

By Tom Wilbur  |    September 26, 2019
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But what...   Read More

World Trade Month: How we can expand world-class pro-innovation standards

By Douglas Petersen  |    May 22, 2019
May is World Trade Month—a celebration of the industries that import and export goods and services around the world. The month offers a good opportunity to examine the significance of international...   Read More

New Report: Advanced manufacturing powering innovative biopharmaceuticals

By Tim McClung  |    May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...   Read More

Clinical trials impact state economies

By John Corea  |    May 3, 2019
A new report from TEConomy Partners, supported by PhRMA, provides estimates of industry-sponsored clinical trial activity in each of the 50 states, including the number of trials active, the number...   Read More

Biopharmaceutical venture capital is spurring innovation and economic growth

By Tim McClung  |    February 11, 2019
The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...   Read More

PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion

By Tim McClung  |    August 9, 2018
PhRMA member companies invested $71.4 billion in research and development (R&D) in 2017, the highest level of investment on record, according to the 2018 PhRMA member annual survey, released in...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates